Afamelanotide Significantly Reduces UV Skin Damage in a Healthy Population – Technical Note 2023 Announcements . Clinical 02.02.2023
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals 2023 Announcements . Clinical 02.02.2023
Afamelanotide Significantly Reduces UV Skin Damage in a Healthy Population 2023 Announcements . Clinical . Regulatory 02.02.2023
Media release: CLINUVEL Trial Results Show Drug Reduces DNA Damage 2023 Announcements . Clinical . Regulatory 16.01.2023
Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum – Technical Note 2023 Announcements . Clinical . Regulatory 16.01.2023
Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum 2023 Announcements . Clinical . Regulatory 16.01.2023
First vitiligo patient enrolled in afamelanotide monotherapy study 2022 Announcements . Clinical . Regulatory 20.10.2022
CLINUVEL submits SCENESSE® label expansion for adolescent EPP patients 2022 Announcements . Clinical . Regulatory 05.09.2022